← Back
Data updated: Jun 28, 2026
bluebird bio
Biotech Pharmaceuticals
bluebird bio is a biotechnology company with 3 FDA-approved products.
2022
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Biologics
bluebird bio's Key Drugs
bluebird bio's core commercial portfolio centers on Skysona, Zynteglo, LYFGENIA — its most strategically important drugs approved in the last 15 years.
bluebird bio's Recent FDA Approvals
New NDA/BLA approvals for bluebird bio over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
bluebird bio's Therapeutic Areas
Disease areas where bluebird bio has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
bluebird bio Pipeline Snapshot
Active clinical trials for bluebird bio across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Skysona leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling